** Shares of Lexicon Pharmaceuticals LXRX.O drop 11.75% to 63 cents before the bell
** Late on Friday, U.S. FDA declined to approve the biopharma company's add-on drug for type 1 diabetes and chronic kidney disease
** Company had previously disclosed its strategic decision to discontinue launch preparations for the drug
** Company had said in November it would reduce its workforce by about 60%, after the U.S. FDA noted deficiencies in its application seeking approval for its diabetes drug
** LXRX to focus on development of other products
** A panel of advisers to the FDA had voted against recommending the drug, sotagliflozin, as an add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease
** Up to last close, stock down ~53% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.